What’s in a name? For one of G2P’s newborn genomic screening studies, quite a bit — as Precision Medicine reports, the collaborative effort has rebranded as BRIDGES-NBS, a change designed to sharpen its identity and steer clear of confusion with unrelated products in the field.
